⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2021European Respiratory Journal

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

Karen M. Olsson Marius M. Hoeper Christine Pausch Ekkehard Grünig Dörte Huscher David Pittrow Stephan Rosenkranz Henning Gall

View at Publisher

Ask AI

Bookmark

Share

Abstract

In patients with pulmonary hypertension associated with interstitial lung disease, pulmonary vascular resistance provides stronger prognostic information than mean pulmonary arterial pressurehttps://bit.ly/3w1QcIS

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Olsson et al. (2021) studied this question.

synapsesocial.com/papers/6a983a84a2c7923eae15f927 https://doi.org/10.1183/13993003.01483-2021

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Pulmonary hypertension in chronic lung disease and hypoxiaOriginal Research · 2018 · 788 citations
2Elevated pulmonary vascular resistance predicts mortality in COPD patientscohort · 2021 · 110 citations
3Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registrycohort · 2020 · 217 citations
4Pulmonary Hypertension in Patients With COPDCohort Study · 2021 · 126 citations
5Comparative Safety and Efficacy of Apixaban and Rivaroxaban During Extended Anticoagulation for Venous Thromboembolism: A Non-randomised Post Hoc Comparison Within the RENOVE TrialEuropean Respiratory Journal · Fri,

More from European Respiratory Journal

Single-cell multi-omics in IPF and COPD: from atlas to impactThu,
A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutationThu,
Cumulative lifecourse cardiovascular health and interstitial lung abnormalitiesThu,
Eurotransplant experience with Model for End-Stage Liver Disease standard exceptions for hepatopulmonary syndrome and portopulmonary hypertensionSun,
Haemodynamic remission and transition off epoprostenol after upfront triple therapy in PAHSun,